Core Viewpoint - Biodexa Pharmaceuticals PLC has appointed Fiona Sharp as Chief Financial Officer and Company Secretary, promoting her to the Board of Directors, effective immediately [2][4]. Group 1: Leadership Changes - Fiona Sharp has been with Biodexa since December 2019, initially serving as Group Financial Controller, and has expanded her responsibilities to include many CFO duties [3]. - Stephen Stamp will step down from his roles as CFO and Company Secretary but will continue as Chief Executive Officer [4]. Group 2: Company Background - Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [5]. - The company's lead development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [5]. Group 3: Product Development - eRapa is an oral capsule formulation of rapamycin, an mTOR inhibitor that plays a significant role in cellular metabolism and tumorigenesis [6]. - Tolimidone is a selective inhibitor of Lyn kinase, showing potential as a first-in-class blood glucose modulating agent [6]. - MTX110 is a formulation of panobinostat designed for direct delivery to tumors, bypassing the blood-brain barrier to reduce systemic toxicity [7]. Group 4: Company Capabilities - Biodexa is supported by three proprietary drug delivery technologies aimed at enhancing the bio-delivery and bio-distribution of medicines [8].

Core Viewpoint - Biodexa Pharmaceuticals PLC is convening a General Meeting to propose four resolutions aimed at restructuring its share capital and enhancing its ability to issue new shares [2][6]. Group 1: Resolutions Proposed - The first resolution proposes the subdivision of each issued ordinary share from £0.001 to one ordinary share of £0.00005 and 19 C deferred shares of £0.00005 each [2][5]. - The second resolution seeks authorization for the Directors to allot equity securities up to a nominal value of £476,954.10, expiring at the conclusion of the Annual General Meeting in 2028 [3]. - The third resolution empowers the Directors to allot equity securities for cash without the application of Section 561 of the Companies Act, also expiring at the conclusion of the Annual General Meeting in 2028 [4]. - The fourth resolution aims to approve and adopt new articles of association, replacing the existing ones [5]. Group 2: Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [7]. - The company's lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [7][8][9][10]. - Biodexa utilizes proprietary drug delivery technologies to enhance the bio-delivery and bio-distribution of its medicines [11].